Glenmark Pharmaceuticals · NSE: GLENMARK · BSE: 532296
Q2 FY24 results · Jul–Sep 2023
Glenmark Pharmaceuticals reported revenue from operations of ₹3,207.38 crore (down 5.0% from Q2 FY23) and net loss of ₹63.55 crore for Q2 FY24 (Jul–Sep 2023), on a consolidated basis.
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3,207.38 | 3,375.25 | −5.0% | 3,401.60 | −5.7% |
| Other income | 1.70 | 97.43 | −98.3% | 20.87 | −91.9% |
| Total income | 3,209.07 | 3,472.68 | −7.6% | 3,422.47 | −6.2% |
| Profit before tax | (124.36) | 480.21 | Turned loss | 333.41 | Turned loss |
| Net profit for the period | (63.55) | 278.67 | Turned loss | 173.13 | Turned loss |
| Attributable to shareholders of the company | (81.95) | — | — | 23.19 | Turned loss |
| EPS, basic (₹) | (2.90) | 9.23 | Turned loss | 5.31 | Turned loss |
| Net margin (%) | -2.0 | 8.3 | 5.1 |
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,233.42 | 2,208.21 | +1.1% | 2,144.38 | +4.2% |
| Other income | 46.22 | 316.73 | −85.4% | 49.36 | −6.4% |
| Total income | 2,279.63 | 2,524.94 | −9.7% | 2,193.74 | +3.9% |
| Profit before tax | 389.37 | 600.52 | −35.2% | 392.04 | −0.7% |
| Net profit for the period | 302.35 | 423.15 | −28.5% | 271.66 | +11.3% |
| EPS, basic (₹) | 10.72 | 15.00 | −28.5% | 9.63 | +11.3% |
| Net margin (%) | 13.5 | 19.2 | 12.7 |
Consolidated
- Filed with BSE
- 15 Nov 2023, 15:11 IST
- Board meeting
- 10 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 15 Nov 2023, 15:11 IST
- Board meeting
- 10 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE